Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Memphasys Ord Shs MPHSF

Healthcare Technology Biotechnology Scientific & Technical Instruments
Memphasys Limited is an Australia-based reproductive biotechnology company. The Company is engaged in developing medical devices, diagnostics, and media with application to assisted reproductive technology (ART) in humans and animals. The Company's product pipeline includes Felix, RoXsta, and AI-Port. Its advanced product, the Felix System, is a patented automated device for quickly and gently separating sperm from a semen sample for use in ART procedures. The Felix device consists of two main components: a console, which supplies electrical power, and a sterile disposable cartridge for sperm isolation and selection. RoXsta is an in-vitro diagnostic device that assesses semen and other bodily fluids for oxidative stress load. RoXsta also has an application as part of a suite of products that can support the animal industry. AI-Port has been developed for the purpose of maintaining the viability of livestock semen for up to seven days at a temperature range of 22 - 25 degrees Celsius.


OTCPK:MPHSF - Post by User

Memphasys Ord Shs
<< Previous
 Bullboard Posts
Next >>
User Avatar Image
(250)
•••
Post by whytestockson Apr 29, 2024 9:15pm
116 Views
Post# 36013864

MorphoSys AG Reports First Quarter 2024 Financial Results

MorphoSys AG Reports First Quarter 2024 Financial Results
Just In: $MOR MorphoSys AG Reports First Quarter 2024 Financial Results&#x2013; Entered into Business Combination Agreement to be acquired by Novartis for &#x20AC; 68.00 per share in cash, representing a total equity value of &#x20AC; 2.7 billion &#x2013; Received all mandatory antitrust approvals for the proposed acquisition by Novartis &#x2013; S...MOR - MorphoSys AG Reports First Quarter 2024 Financial Results

<< Previous
 Bullboard Posts
Next >>
Dealroom for high-potential pre-IPO opportunities